Globus Medical

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Globus Medical achieves record revenue, plans NuVasive merger

Globus Medical (GMED) delivered strong financial performance in 2022, with record revenue and notable growth across key segments.
The planned merger with NuVasive and focus on product innovation position the company for future success and market leadership.
Challenges such as retaining talent and addressing international market dynamics require strategic solutions for sustained growth.
Opportunities lie in diversifying revenue streams, expanding product offerings, and leveraging international markets for continued success.

Globus Medical (GMED) reports record Q1 sales, eyes growth opportunities

Globus Medical (GMED) delivered a strong Q1 performance with record sales and profit growth, driven by strategic initiatives and market demand. While facing challenges like merger delays and potential competition, the company's focus on innovation, technology leadership, and market recognition positions it well for sustained growth and success.

Globus Medical posts record Q2 sales, eyes growth through innovation

Globus Medical delivered a strong Q2 performance with record sales and profitability, driven by innovation and market expansion.
While facing integration challenges post-merger, the company's focus on growth segments and product innovation positions it well for future success.
Opportunities lie in expanding market presence, driving innovation, and capitalizing on technological advancements to sustain growth momentum.

Globus Medical reports record Q3 sales, eyes growth opportunities

Globus Medical's Q3 performance reflects robust sales growth, steady EPS, and progress towards revenue targets, underpinned by innovative product launches and strategic integration efforts.
While facing challenges in hiring and cost synergies, the company's focus on talent acquisition, cost management, and segment-specific strategies positions them well for future growth.
Opportunities lie in new product launches, technological advancements, and streamlined operations through sales force integration, indicating a promising trajectory for Globus Medical's continued success.

Globus Medical (GMED) reports record revenue in 2023, eyes growth amid challenges

Globus Medical (GMED) delivered strong financial results in 2023, driven by the NuVasive merger, with a focus on integration and innovation. While facing challenges from dissynergies and market competition, GMED is poised to capitalize on growth opportunities through strategic initiatives and product launches.

Globus Medical excels in Q1 2024, eyes Enabling Technologies growth

Globus Medical's Q1 2024 showcased exceptional sales growth, margin improvement, and strategic initiatives. Despite challenges in integration and product rollout timing, the company is poised for long-term success. Opportunities in Enabling Technologies and cost leverage position Globus for continued growth.

Globus Medical excels in Q3, eyes margin improvement strategies

Globus Medical's Q3 performance reflects strong financial results, innovation, and market expansion. While challenges in margin improvement persist, the company's strategic focus on cost optimization and product development sets the stage for continued growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK CITY, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

GMED STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Shareholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.

ATTENTION Globus Medical, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Globus Medical, Inc. (“Globus” or the “Company”) (NYSE:GMED) on behalf of Globus stockholders. Our investigation concerns whether Globus has violated the federal securities laws and/or engaged in other unlawful business practices.

GLOBUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Globus Medical, Inc. on Behalf of Globus Stockholders and Encourages Investors to Contact the Firm

GMED ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Globus Medical, Inc. Shareholders Who Lost Money

NEW YORK CITY, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

GMED SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Shareholders to Contact the Firm!

NEW YORK CITY, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

GMED INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Shareholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.

GMED STOCK ALERT: Levi & Korsinsky Notifies Globus Medical, Inc. Investors of an Ongoing Investigation

Globus Medical, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- GMED

Globus Medical, Inc. (GMED) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)---- $GMED #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE: GMED). The investigation concerns whether Globus Medical and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On August 13, 2024, in a filing with the U.S. Securities and Exchange Commission, Globus Medical.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Globus Medical, Inc. (GMED)

NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.

Investors who lost money on Globus Medical, Inc. should contact Levi & Korsinsky about an ongoing investigation - GMED

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE: GMED) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Globus Medical investments or would like to inquire about potentially pursuing claims to recover your loss under the federal.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors

Globus Medical, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - GMED

NEW YORK CITY, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

GMED STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Investors to Contact the Firm!

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE: GMED) investors concerning the Company's possible violations of federal securities laws. On August 13, 2024, the FDA published a warning letter to Globus Medical regarding an inspection of the Company's Class II Excelsius GPS (EGPS) surgical robot, stating that the inspection revealed that “these devices are adulterated” and are n.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors

Brightcove

SCOTTS VALLEY, Calif.--(BUSINESS WIRE)--Paystand marks 5th year on Inc. 5000 list with 1 million on Paystand Network and $10 billion in cumulative transactions.

Paystand Marks Its Fifth Year on Inc. 5000 with the Major Acquisition of Teampay and the Founding of Paystand.org

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE: GMED) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 13, 2024, the FDA published a warning letter to Globus Medical regarding an inspection of the Company's Class II Excelsius GPS (EGPS) surgical robot, stating.

The Law Offices of Frank R. Cruz Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.

ATTENTION GMED SHAREHOLDERS: Investors who lost money on Globus Medical, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK CITY, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

GMED SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Investors to Contact the Firm!

NEW YORK CITY, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

GMED INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Investors to Contact the Firm!

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Globus Medical (GMED) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Globus Medical (GMED) is a Strong Growth Stock

Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.

Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up

Globus Medical, Inc. (NYSE:GMED ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development and IR Daniel Scavilla - President and CEO Keith Pfeil - COO and CFO Conference Call Participants Matthew Miksic - Barclays Vikramjeet Chopra - Wells Fargo Shagun Singh - RBC CM Steve Lichtman - Oppenheimer David Saxon - Needham & Company Matthew O'Brien - Piper Sandler Jason Wittes - ROTH Matthew Blackman - Stifel Ryan Zimmerman - BTIG Ravi Mishra - Truist Craig Bijou - BofA Operator Welcome to Globus Medical's Second Quarter 2024 Earnings Call. At this time, all lines will be on mute and a Q&A session will be held after the prepared remarks.

Globus Medical, Inc. (GMED) Q2 2024 Earnings Call Transcript

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

News for Globus Medical Stock (GMED)